NCT02684838 (VIGILANT) is a clinical trial in CNS Tumor, sponsored by Arbor Pharmaceuticals, Inc..

Who is sponsoring NCT02684838?

NCT02684838 is sponsored by Arbor Pharmaceuticals, Inc..

Is NCT02684838 still recruiting?

NCT02684838 is currently completed. Last updated 10 November 2025.

Last reviewed 2025-11-10 · How we verify

NCT02684838: VIGILANT

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Vigilant ObservatIon of GlIadeL WAfer ImplaNT Registry

Completed Last updated 10 November 2025

What this trial tests

trial in CNS Tumor in 272 participants. Completed in 23 June 2025.

Timeline

26 April 2016

Primary endpoint
23 June 2025

23 June 2025

Quick facts

Lead sponsor	Arbor Pharmaceuticals, Inc.
Status	Completed
Study type	OBSERVATIONAL
Enrollment	272
Start date	26 April 2016
Primary completion	23 June 2025
Estimated completion	23 June 2025
Sites	31 locations across United States

Conditions studied

CNS Tumor — all drugs for CNS Tumor →

Sponsor

Arbor Pharmaceuticals, Inc. — full company profile →

Who can join

18 and older, any sex, with CNS Tumor. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a prospective, observational registry in patients who have been prescribed Gliadel Wafer by the physician as part of usual care.

Publications & conference data

7 peer-reviewed publications reference this trial (live from Europe PMC):

Rationale and design of the 500-patient, 3-year, and prospective Vigilant ObservatIon of GlIadeL WAfer ImplaNT registry.
Lillehei KO, Kalkanis SN, Liau LM, Mydland DE, et al · · 2018 · cited 13× · PMID 29206049 · DOI 10.2217/cns-2017-0036
Localized treatment of glioblastoma: a review of clinical strategies and advances in drug delivery systems.
Pesce C, Rodella G, Fragassi A, Garofalo M, et al · · 2025 · cited 1× · PMID 40874730 · DOI 10.1080/17435889.2025.2550239
ACTR-54. VIGILANT OBSERVATION OF GLIADEL WAFER IMPLANT (VIGILANT) REGISTRY: INTERIM ANALYSIS
Lillehei K, Kalkanis S, Liau L, Olson J, et al · · 2019
ACTR-57. A PHASE 1/2 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF BLOOD-BRAIN BARRIER (BBB) OPENING WITH A NINE-EMITTER IMPLANTABLE ULTRASOUND DEVICE IN RECURRENT GLIOBLASTOMA PATIENTS PRIOR TO CARBOPLATIN
Idbaih A, Ducray F, DeGroot J, Stupp R, et al · · 2019
ACTR-53. MGMT PROMOTER METHYLATION ANALYSIS FOR ALLOCATING COMBINED CCNU/TMZ CHEMOTHERAPY: LESSONS LEARNED FROM THE CeTeG/NOA-09 TRIAL
Tzaridis T, Schäfer N, Weller J, Steinbach J, et al · · 2019
ACTR-55. OPTIMIZED TREAT-RESECT-TREAT STUDY DESIGN FOR CONVECTION-ENHANCED DELIVERY OF A FIRST-IN-CLASS BIOLOGIC IN THE TREATMENT OF GLIOBLASTOMA
Immidisetti A, Nwagwu C, Shawn Carbonell W, Carbonell A. · · 2019
ACTR-56. PHASE II TRIAL OF NILOTINIB IN PDGFR-ALPHA ENRICHED RECURRENT GLIOBLASTOMA
Picconi D, Juarez T, Kesari S. · · 2019

Verify or expand the search:

Other recruiting trials for CNS Tumor

Currently open trials in the same condition.

NCT07236840 — Self-administered Remote Neurological Examination Using Mobile Application in Patients With Brain Tumors · recruiting
NCT05982691 — Development of Asian Consortium for Data Collection and Clinical Trial of CNS Tumors · recruiting
NCT04732065 — ONC206 for Treatment of Newly Diagnosed, Recurrent Diffuse Midline Gliomas, and Other Recurrent Malignant CNS Tumors · Phase 1 · recruiting
NCT03838042 — INFORM2 Study Uses Nivolumab and Entinostat in Children and Adolescents With High-risk Refractory Malignancies · Phase 1, PHASE2 · recruiting

Other Arbor Pharmaceuticals, Inc. trials

Trials by the same sponsor.

NCT06247488 — Abuse Potential of HORIZANT With and Without Oxycodone in Healthy, Nondependent Recreational Opioid Users · Phase 4 · completed
NCT06097676 — An Abuse Potential Study of Orally Administered HORIZANT in Healthy, Non-dependent, Recreational Drug Users · Phase 4 · completed
NCT03659929 — Adult Attention Deficit Hyperactivity Disorder (ADHD) Study With Amphetamine Sulfate · Phase 3 · completed
NCT02235909 — An Efficacy and Safety Study in Children 6 to Less Than 18 Years of Age With Hypertension · Phase 3 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02684838 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Arbor Pharmaceuticals, Inc.
Last refreshed: 10 November 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02684838.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing